share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

CRISPR Therapeutics | 4：持股变动声明-高管 Kulkarni Samarth
美股sec公告 ·  04/18 05:50
牛牛AI助手已提取核心信息
CRISPR Therapeutics CEO Samarth Kulkarni completed a stock transaction on April 15, 2024, involving the sale of company shares. Kulkarni sold a total of 19,582 shares of common stock at prices ranging from $59.8819 to $60.4003, resulting in a total market value of approximately $1,173,231.52. Prior to the sales, Kulkarni exercised options to acquire the same number of shares at a price of $19.12 per share. Following the transactions, Kulkarni directly holds 208,122 shares of CRISPR Therapeutics. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.
CRISPR Therapeutics CEO Samarth Kulkarni completed a stock transaction on April 15, 2024, involving the sale of company shares. Kulkarni sold a total of 19,582 shares of common stock at prices ranging from $59.8819 to $60.4003, resulting in a total market value of approximately $1,173,231.52. Prior to the sales, Kulkarni exercised options to acquire the same number of shares at a price of $19.12 per share. Following the transactions, Kulkarni directly holds 208,122 shares of CRISPR Therapeutics. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.
CRISPR Therapeutics首席执行官萨玛斯·库尔卡尼于2024年4月15日完成了一笔涉及出售公司股票的股票交易。库尔卡尼共出售了19,582股普通股，价格从59.8819美元到60.4003美元不等，总市值约为1,173,231.52美元。在出售之前，库尔卡尼行使了期权，以每股19.12美元的价格收购了相同数量的股票。交易完成后，库尔卡尼直接持有CRISPR Therapeutics的208,122股股份。此外，库尔卡尼通过库尔卡尼2023年GRAT拥有20万股股票的间接实益所有权。
CRISPR Therapeutics首席执行官萨玛斯·库尔卡尼于2024年4月15日完成了一笔涉及出售公司股票的股票交易。库尔卡尼共出售了19,582股普通股，价格从59.8819美元到60.4003美元不等，总市值约为1,173,231.52美元。在出售之前，库尔卡尼行使了期权，以每股19.12美元的价格收购了相同数量的股票。交易完成后，库尔卡尼直接持有CRISPR Therapeutics的208,122股股份。此外，库尔卡尼通过库尔卡尼2023年GRAT拥有20万股股票的间接实益所有权。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

译文内容由第三方软件翻译。


牛牛AI助手部分由第三方人工智能模型基于资讯内容自动生成，只对中国内地以外的地区提供。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。